• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

Sanofi, Orano Strike Deal to Develop Radioligand Medicines for Rare Cancers
Sanofi, Orano Strike Deal to Develop Radioligand Medicines for Rare Cancers

October 17th 2024

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.

FDA Approves AbbVie’s Vyalev for Advanced Parkinson Disease
FDA Approves AbbVie’s Vyalev for Advanced Parkinson Disease

October 17th 2024

Stock.adobe.com
ISTH Issues Survey for World Thrombosis Day

October 17th 2024

Rust Felix
Managing Data from Clinical Trials: Q&A with Rust Felix

October 17th 2024

Findings from the NIAGRA Trial in Bladder Cancer and Mechanisms of Resistance
Findings from the NIAGRA Trial in Bladder Cancer and Mechanisms of Resistance

October 17th 2024

‘Selling a Vision’: Today’s Playbook for Startups

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

 The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Conference Coverage

View All
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer

June 3rd 2024

Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status
Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status

June 3rd 2024

Latest Videos
Podcasts

All News